Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Related Experiment Videos

VEGF in physiological process and thyroid disease.

M Klein1, B Catargi

  • 1Service d'endocrinologie, CHU de Nancy, rue du Morvan, 54500 Vandoeuvre-lès-Nancy, France. m.klein@chu-nancy.fr

Annales D'Endocrinologie
|November 10, 2007
PubMed
Summary
This summary is machine-generated.

Related Concept Videos

You might also read

Related Articles

Articles linked to this work by shared authors, journal, and citation graph.

Sort by
Same author

High glycemic variability: An underestimated determinant of stroke functional outcome following large vessel occlusion.

Revue neurologique·2022
Same author

Bioelectronic organ-based sensor for microfluidic real-time analysis of the demand in insulin.

Biosensors & bioelectronics·2018
Same author

Practical management of diabetes patients before, during and after surgery: A joint French diabetology and anaesthesiology position statement.

Diabetes & metabolism·2018
Same author

Practical implementation, education and interpretation guidelines for continuous glucose monitoring: A French position statement.

Diabetes & metabolism·2017
Same author

Saccharide-induced modulation of photoluminescence lifetime in microgels.

Physical chemistry chemical physics : PCCP·2016
Same author

Indication, organization, practical implementation and interpretation guidelines for retrospective CGM recording: A French position statement.

Diabetes & metabolism·2015
Same journal

[18F]F-DOPA and [18F]F-FDG PET/CT for staging advanced medullary thyroid cancer.

Annales d'endocrinologie·2026
Same journal

Corrigendum to 'Pink adipose tissue: A paradigm of adipose tissue plasticity' [Ann. Endocrinol. 85 (2004) 248-51].

Annales d'endocrinologie·2026
Same journal

Intraoperative location of parathyroid glands during total thyroidectomy: a systematic review of the literature according to the PRISMA method.

Annales d'endocrinologie·2026
Same journal

Clinical and genetic diagnosis of PHP1A associated with hypogonadism in a young male: A case report.

Annales d'endocrinologie·2026
Same journal

Autoimmune features in acquired generalized lipodystrophy and anti-perilipin 1 antibodies: A case report.

Annales d'endocrinologie·2026
Same journal

The diagnostic challenge of occult glucocorticoid exposure causing Cushing's syndrome.

Annales d'endocrinologie·2026
See all related articles

Vascular endothelial growth factor (VEGF) drives thyroid tumor growth and metastasis. Targeting VEGF with inhibitors offers a promising therapeutic strategy for thyroid cancer.

Area of Science:

  • Oncology
  • Physiology
  • Molecular Biology

Background:

  • Angiogenesis, the formation of new blood vessels, is crucial for physiological processes.
  • Vascular Endothelial Growth Factor (VEGF) is a key regulator in both normal and cancerous thyroid conditions.
  • The VEGF family comprises multiple members (VEGF-A, -B, -C, -D, -E, -F, and PlGF) with diverse roles.

Purpose of the Study:

  • To investigate the role of VEGF in thyroid angiogenesis and cancer progression.
  • To highlight VEGF's involvement in tumor growth, metastasis, and patient outcomes.
  • To establish VEGF as a therapeutic target for thyroid malignancies.

Main Methods:

  • Analysis of VEGF expression in thyroid tissues.
  • Correlation of VEGF levels with tumor characteristics and patient prognosis.

Related Experiment Videos

  • Review of therapeutic strategies targeting VEGF.

    • Main Results:

    • VEGF-A promotes tumor vascularization and metastasis.
    • VEGF-C and VEGF-D contribute to lymph node metastasis in papillary thyroid carcinomas.
    • Elevated VEGF expression is linked to poorer outcomes in papillary thyroid carcinomas.

    Conclusions:

    • VEGF plays a critical role in thyroid cancer development and spread.
    • VEGF is a significant biomarker for predicting prognosis in thyroid cancer.
    • Angiogenesis inhibitors targeting VEGF represent a key therapeutic approach for thyroid cancer.